Key result
Pre-transplant CMV-seronegative heart transplant recipients had a significantly higher incidence of CMV infection compared to seropositive recipients (77.8% vs 50.9%, P=0.007).
Population
294 heart transplant recipients on immunosuppression
Design
Cohort
Follow-up
mean 44.9±28.4 months (range 1.0-100.8 months)
Authors
Loading...
May support enhanced CMV monitoring in seronegative recipients; leaves optimal prevention strategies open for prospective trials.
Cohort (n=294)
Absolute Event Rate: 77.8% vs 50.9%
p-value: p=0.007
Prospective monitoring reveals a high incidence of CMV infection in heart transplant recipients, particularly in CMV-seronegative patients receiving organs from CMV-seropositive donors, though many infections remain asymptomatic.
Grossi et al. (1995) conducted a cohort in Heart transplant recipients (n=294). Pre-transplant CMV seronegative status vs. Pre-transplant CMV seropositive status was evaluated on Overall incidence of CMV infection (p=0.007). Pre-transplant CMV-seronegative heart transplant recipients had a significantly higher incidence of CMV infection compared to seropositive recipients (77.8% vs 50.9%, P=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: